Artificial Valve Endocarditis Reduction Trial (AVERT): Protocol of a multicenter randomized trial

Hartzell V Schaff, Thierry Carrel, James M. Steckelberg, Gary L. Grunkemeier, Richard Holubkov

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background and aim of the study: This article presents the protocol of the Artificial Valve Endocarditis Reduction Trial (AVERT), a multicenter, international randomized trial to assess the efficacy of the SilzoneTM coating of St. Jude Medical® Masters Series mechanical heart valves in the prevention of prosthetic heart valve endocarditis (PVE). A total of 4,400 eligible patients will be randomized within three years of study commencement at 17 participating clinical centers in North America and Europe, with study completion within four years. Eligibility criteria: Eligible patients are candidates for St. Jude mechanical valves with either the Silzone or conventional cuff, in the mitral and/or aortic position, who give informed written consent to participate. Major exclusion criteria are the presence of prosthetic valves that do not require replacement, and the need for tricuspid valve replacement. Bypass surgery and valve repair are allowed during the implant operation. Patients will be randomized using an envelope-based intraoperative randomization scheme, stratified by clinical center and by the presence of endocarditis at the time of surgery. Follow up: Patients will be contacted at discharge, three months, and each anniversary of the implant procedure. A brief follow up survey, administered via clinic interview, telephone or mail, will elicit events associated with possible endocarditis (unexplained fever, worsening angina, hospitalization) that will initiate contact with the patient's following physician. Outcome analysis: The primary PVE endpoint will be based upon a published algorithm, with two infectious disease specialists making the final determination of cases classified as possible endocarditis. Study data will be periodically reviewed by a Data Safety Monitoring Board. The primary analysis will be an intention-to-treat comparison of freedom from PVE curves between the Silzone and conventional cuff treatment groups. Conclusions: AVERT will provide much-needed information on the effectiveness of Silzone in preventing PVE, as well as practice patterns and outcomes of valve replacement.

Original languageEnglish (US)
Pages (from-to)131-139
Number of pages9
JournalJournal of Heart Valve Disease
Volume8
Issue number2
StatePublished - 1999
Externally publishedYes

Fingerprint

Clinical Protocols
Endocarditis
Multicenter Studies
Heart Valves
Clinical Trials Data Monitoring Committees
Tricuspid Valve
Postal Service
Anniversaries and Special Events
Random Allocation
North America
Informed Consent
Communicable Diseases
Hospitalization
Fever
Interviews
Physicians

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Schaff, H. V., Carrel, T., Steckelberg, J. M., Grunkemeier, G. L., & Holubkov, R. (1999). Artificial Valve Endocarditis Reduction Trial (AVERT): Protocol of a multicenter randomized trial. Journal of Heart Valve Disease, 8(2), 131-139.

Artificial Valve Endocarditis Reduction Trial (AVERT) : Protocol of a multicenter randomized trial. / Schaff, Hartzell V; Carrel, Thierry; Steckelberg, James M.; Grunkemeier, Gary L.; Holubkov, Richard.

In: Journal of Heart Valve Disease, Vol. 8, No. 2, 1999, p. 131-139.

Research output: Contribution to journalArticle

Schaff, HV, Carrel, T, Steckelberg, JM, Grunkemeier, GL & Holubkov, R 1999, 'Artificial Valve Endocarditis Reduction Trial (AVERT): Protocol of a multicenter randomized trial', Journal of Heart Valve Disease, vol. 8, no. 2, pp. 131-139.
Schaff, Hartzell V ; Carrel, Thierry ; Steckelberg, James M. ; Grunkemeier, Gary L. ; Holubkov, Richard. / Artificial Valve Endocarditis Reduction Trial (AVERT) : Protocol of a multicenter randomized trial. In: Journal of Heart Valve Disease. 1999 ; Vol. 8, No. 2. pp. 131-139.
@article{53feba8bb516498e89bcbbcfc099aa0f,
title = "Artificial Valve Endocarditis Reduction Trial (AVERT): Protocol of a multicenter randomized trial",
abstract = "Background and aim of the study: This article presents the protocol of the Artificial Valve Endocarditis Reduction Trial (AVERT), a multicenter, international randomized trial to assess the efficacy of the SilzoneTM coating of St. Jude Medical{\circledR} Masters Series mechanical heart valves in the prevention of prosthetic heart valve endocarditis (PVE). A total of 4,400 eligible patients will be randomized within three years of study commencement at 17 participating clinical centers in North America and Europe, with study completion within four years. Eligibility criteria: Eligible patients are candidates for St. Jude mechanical valves with either the Silzone or conventional cuff, in the mitral and/or aortic position, who give informed written consent to participate. Major exclusion criteria are the presence of prosthetic valves that do not require replacement, and the need for tricuspid valve replacement. Bypass surgery and valve repair are allowed during the implant operation. Patients will be randomized using an envelope-based intraoperative randomization scheme, stratified by clinical center and by the presence of endocarditis at the time of surgery. Follow up: Patients will be contacted at discharge, three months, and each anniversary of the implant procedure. A brief follow up survey, administered via clinic interview, telephone or mail, will elicit events associated with possible endocarditis (unexplained fever, worsening angina, hospitalization) that will initiate contact with the patient's following physician. Outcome analysis: The primary PVE endpoint will be based upon a published algorithm, with two infectious disease specialists making the final determination of cases classified as possible endocarditis. Study data will be periodically reviewed by a Data Safety Monitoring Board. The primary analysis will be an intention-to-treat comparison of freedom from PVE curves between the Silzone and conventional cuff treatment groups. Conclusions: AVERT will provide much-needed information on the effectiveness of Silzone in preventing PVE, as well as practice patterns and outcomes of valve replacement.",
author = "Schaff, {Hartzell V} and Thierry Carrel and Steckelberg, {James M.} and Grunkemeier, {Gary L.} and Richard Holubkov",
year = "1999",
language = "English (US)",
volume = "8",
pages = "131--139",
journal = "Journal of Heart Valve Disease",
issn = "0966-8519",
publisher = "ICR Publishers Ltd",
number = "2",

}

TY - JOUR

T1 - Artificial Valve Endocarditis Reduction Trial (AVERT)

T2 - Protocol of a multicenter randomized trial

AU - Schaff, Hartzell V

AU - Carrel, Thierry

AU - Steckelberg, James M.

AU - Grunkemeier, Gary L.

AU - Holubkov, Richard

PY - 1999

Y1 - 1999

N2 - Background and aim of the study: This article presents the protocol of the Artificial Valve Endocarditis Reduction Trial (AVERT), a multicenter, international randomized trial to assess the efficacy of the SilzoneTM coating of St. Jude Medical® Masters Series mechanical heart valves in the prevention of prosthetic heart valve endocarditis (PVE). A total of 4,400 eligible patients will be randomized within three years of study commencement at 17 participating clinical centers in North America and Europe, with study completion within four years. Eligibility criteria: Eligible patients are candidates for St. Jude mechanical valves with either the Silzone or conventional cuff, in the mitral and/or aortic position, who give informed written consent to participate. Major exclusion criteria are the presence of prosthetic valves that do not require replacement, and the need for tricuspid valve replacement. Bypass surgery and valve repair are allowed during the implant operation. Patients will be randomized using an envelope-based intraoperative randomization scheme, stratified by clinical center and by the presence of endocarditis at the time of surgery. Follow up: Patients will be contacted at discharge, three months, and each anniversary of the implant procedure. A brief follow up survey, administered via clinic interview, telephone or mail, will elicit events associated with possible endocarditis (unexplained fever, worsening angina, hospitalization) that will initiate contact with the patient's following physician. Outcome analysis: The primary PVE endpoint will be based upon a published algorithm, with two infectious disease specialists making the final determination of cases classified as possible endocarditis. Study data will be periodically reviewed by a Data Safety Monitoring Board. The primary analysis will be an intention-to-treat comparison of freedom from PVE curves between the Silzone and conventional cuff treatment groups. Conclusions: AVERT will provide much-needed information on the effectiveness of Silzone in preventing PVE, as well as practice patterns and outcomes of valve replacement.

AB - Background and aim of the study: This article presents the protocol of the Artificial Valve Endocarditis Reduction Trial (AVERT), a multicenter, international randomized trial to assess the efficacy of the SilzoneTM coating of St. Jude Medical® Masters Series mechanical heart valves in the prevention of prosthetic heart valve endocarditis (PVE). A total of 4,400 eligible patients will be randomized within three years of study commencement at 17 participating clinical centers in North America and Europe, with study completion within four years. Eligibility criteria: Eligible patients are candidates for St. Jude mechanical valves with either the Silzone or conventional cuff, in the mitral and/or aortic position, who give informed written consent to participate. Major exclusion criteria are the presence of prosthetic valves that do not require replacement, and the need for tricuspid valve replacement. Bypass surgery and valve repair are allowed during the implant operation. Patients will be randomized using an envelope-based intraoperative randomization scheme, stratified by clinical center and by the presence of endocarditis at the time of surgery. Follow up: Patients will be contacted at discharge, three months, and each anniversary of the implant procedure. A brief follow up survey, administered via clinic interview, telephone or mail, will elicit events associated with possible endocarditis (unexplained fever, worsening angina, hospitalization) that will initiate contact with the patient's following physician. Outcome analysis: The primary PVE endpoint will be based upon a published algorithm, with two infectious disease specialists making the final determination of cases classified as possible endocarditis. Study data will be periodically reviewed by a Data Safety Monitoring Board. The primary analysis will be an intention-to-treat comparison of freedom from PVE curves between the Silzone and conventional cuff treatment groups. Conclusions: AVERT will provide much-needed information on the effectiveness of Silzone in preventing PVE, as well as practice patterns and outcomes of valve replacement.

UR - http://www.scopus.com/inward/record.url?scp=0032948422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032948422&partnerID=8YFLogxK

M3 - Article

C2 - 10224570

AN - SCOPUS:0032948422

VL - 8

SP - 131

EP - 139

JO - Journal of Heart Valve Disease

JF - Journal of Heart Valve Disease

SN - 0966-8519

IS - 2

ER -